Thiel Capital

Pioneering a biologically enhanced future for humanity.

Network Bio develops a platform that serves as a centralized repository for clinical and molecular data. This enables researchers to identify patterns and correlations, facilitating precision medicine approaches for common human diseases.

EnClear Therapies develops device-based therapies for treating neurodegenerative diseases by removing toxic proteins from cerebrospinal fluid. Its initial targets are Amyotrophic Lateral Sclerosis (ALS) and Progressive Supranuclear Palsy (PSP). Incorporated in 2018, the company is based in Newburyport, Massachusetts.

Rollup is a software company that provides a collaborative platform aimed at enhancing the development and optimization of complex hardware and systems. Its primary offering leverages model-based systems engineering, which integrates engineering analysis, designs, and documentation into a cohesive framework. This approach allows teams to streamline their processes, reducing reliance on costly tools and specialized software licenses, while also minimizing the need for extensively trained engineers. By facilitating real-time communication and system modeling, Rollup enables teams to efficiently collaborate and innovate in the creation of advanced hardware solutions.

Neros Technologies specializes in autonomous drone services, offering cost-effective unmanned systems designed for large-scale deployment. Their drones are optimized for long-range missions and resistant to electronic warfare, serving clients primarily in the defense sector.

Quantum system develops manufactures and sells unmanned aerial systems, which provide aerial intelligence to commercial and governmental clients around the world.

Heading Health is a technology-driven platform enhancing access to affordable mental health care. It offers personalized treatment solutions, combining evidence-based therapeutics with advanced technologies like transcranial magnetic stimulation, telepsychiatry, and intramuscular ketamine.

Generation Prime is a digital healthcare platform focused on providing women's healthcare services, particularly in the area of in-vitro fertilization (IVF) and related family planning and medical needs. The company aims to enhance accessibility and affordability of IVF treatments through a closed-loop system that integrates technology with healthcare delivery. By facilitating clinic roll-ups, Generation Prime enables healthcare professionals to offer services at reduced costs, thereby improving patient care and experience.

SPARK Neuro Inc. is a neuroscience company focused on quantifying brain data to enhance audience engagement in the advertising and entertainment sectors, as well as improving clinical care and therapeutic discovery in healthcare. Founded in 2013 and headquartered in New York, the company utilizes advanced neuroscience tools, including patented neural metrics and machine learning algorithms, to analyze brain activity. Its flagship product, SPARK Scan, is a 10-minute EEG-based evaluation that detects early signs of changes in brain function. By partnering with prestigious institutions, SPARK Neuro aims to deepen the understanding of neurological and psychiatric conditions while making brain health measurement and care more accessible for healthcare professionals.

Ready.net is a software development company that specializes in creating business and operational tools for internet service providers (ISPs). Founded in 2020 and headquartered in San Francisco, California, the company offers a product called Back Office Secret Sauce (BOSS). This innovative software enables ISP subscribers to manage their networks independently, facilitating tasks such as upgrading service plans, selecting additional services, paying bills online, and receiving assistance through a chatbot. Ready.net aims to enhance the operational efficiency of local ISPs while providing a user-friendly experience for their customers.

Alloy Therapeutics is a biotechnology company based in Waltham, Massachusetts, founded in 2017. The company focuses on democratizing access to essential drug discovery platforms and services, primarily through its Alloy-Gx platform. This innovative platform features a royalty-free suite of immunocompetent transgenic mice that facilitate in vivo human antibody discovery. Alloy Therapeutics has developed humanized transgenic antibody discovery technology, which offers broad, non-exclusive access to drug discovery tools, allowing scientists to engage in their antibody projects more efficiently and effectively. The company's mission is to enhance the drug discovery process by providing accessible and advanced resources for researchers in the field.

Vienna is a smart canvas for ideas. It is a place to collect thoughts and everything that comes with photos, videos, code, music, files, and, of course, text. They serve services for creators, students, and teams to build and discover ideas.

Inflection Points is a company that specializes in providing training and recruitment services within the bitcoin and cryptocurrency industry. It operates an employment and training platform designed to facilitate connections between employers and job seekers in this sector. The platform enables employers to search for and connect with candidates for various job vacancies, while also offering candidates opportunities to explore roles within the bitcoin and crypto world.

Regent designs and manufactures electric flying machines, known as seagliders, for coastal transportation. These wing-in-ground-effect craft operate a few meters above water's surface, combining airplane speed with boat operating costs. Seagliders aim to revolutionize regional travel by connecting coastal cities and islands efficiently and sustainably.

Mynaric AG, established in 2009 and headquartered in Gilching, Germany, specializes in laser communication solutions for high-speed, long-distance wireless data transmission between moving objects. The company offers a range of terminals including air-to-ground, air-to-air, space terminals, and optical ground stations, catering to applications in space, air, and ground sectors. Its products facilitate secure, high-data rate connectivity for satellite constellations, airborne networks, and other mobility-based applications.

Ex-human develops an AI platform that creates digital human characters for interactive conversations across text, audio, images and video. The platform enables creators and businesses to generate engaging interactions with features such as AI chat, text-to-image generation, customizable templates, and voice chat, supporting content creation workflows and daily use. It serves industries including gaming, dating, chatbots, and influencer marketing, helping organizations enhance engagement and streamline content generation.

Bullish Global is a new blockchain-based cryptocurrency exchange designed to combine the performance, user privacy, and compliance offered by central order book technology with the vertically integrated user benefits of decentralized finance (DeFi) market architecture.

Angiex is a biotechnology company developing vascular-targeted therapies for solid cancers. Founded by renowned scientists, Angiex focuses on fundamental aspects of endothelial biology, particularly angiogenesis. Its lead product is an antibody-drug conjugate therapy designed to deliver conjugated payloads directly to the nucleus in tumor cells and activated endothelium.

ATAI Life Sciences is a biotechnology company focused on developing therapies for mental health disorders, leveraging psychedelic compounds and neuroscience-based approaches. It operates a platform for mental health drug discovery and development and collaborates with partners and research institutions to advance its pipeline, which includes VLS-01, a buccal-film DMT candidate for treatment-resistant depression, and EMP-01, an oral MDMA therapy for social anxiety disorder, along with a drug discovery program aimed at identifying non-hallucinogenic 5-HT2A receptor agonists for depression. The company is based in Munich, Germany, with additional offices in Berlin and London.

Voices is a live video streaming platform that allows creators to monetize their work through donations and subscriptions. Voices will assist content creators in making this a "stunning mass phenomenon," as well as "promote the growth of the creative economy's middle class."

Rational Vaccines is a biotechnology company focused on developing vaccines for herpes simplex virus (HSV) and related diseases. It aims to revolutionize treatment, prevention, and diagnosis by creating rationally engineered, live-attenuated viral vaccines.

ATAI Life Sciences is a biotechnology company focused on developing therapies for mental health disorders, leveraging psychedelic compounds and neuroscience-based approaches. It operates a platform for mental health drug discovery and development and collaborates with partners and research institutions to advance its pipeline, which includes VLS-01, a buccal-film DMT candidate for treatment-resistant depression, and EMP-01, an oral MDMA therapy for social anxiety disorder, along with a drug discovery program aimed at identifying non-hallucinogenic 5-HT2A receptor agonists for depression. The company is based in Munich, Germany, with additional offices in Berlin and London.

Ready.net is a software development company that specializes in creating business and operational tools for internet service providers (ISPs). Founded in 2020 and headquartered in San Francisco, California, the company offers a product called Back Office Secret Sauce (BOSS). This innovative software enables ISP subscribers to manage their networks independently, facilitating tasks such as upgrading service plans, selecting additional services, paying bills online, and receiving assistance through a chatbot. Ready.net aims to enhance the operational efficiency of local ISPs while providing a user-friendly experience for their customers.

Founded in 2014, Compass Therapeutics is a clinical-stage biopharmaceutical company developing antibody therapeutics to treat solid tumors and hematological malignancies. Its pipeline includes CTX-471, an agonistic antibody of CD137 for immune cell activation, currently in Phase I trials; CTX-8371, a bispecific antibody targeting PD-1 and PD-L1, in IND-enabling studies; and CTX-009, a bispecific antibody inhibiting DLL4 and VEGF-A signaling, completed Phase I and is in Phase Ib combination with chemotherapy.

ATAI Life Sciences is a biotechnology company focused on developing therapies for mental health disorders, leveraging psychedelic compounds and neuroscience-based approaches. It operates a platform for mental health drug discovery and development and collaborates with partners and research institutions to advance its pipeline, which includes VLS-01, a buccal-film DMT candidate for treatment-resistant depression, and EMP-01, an oral MDMA therapy for social anxiety disorder, along with a drug discovery program aimed at identifying non-hallucinogenic 5-HT2A receptor agonists for depression. The company is based in Munich, Germany, with additional offices in Berlin and London.

EnClear Therapies develops device-based therapies for treating neurodegenerative diseases by removing toxic proteins from cerebrospinal fluid. Its initial targets are Amyotrophic Lateral Sclerosis (ALS) and Progressive Supranuclear Palsy (PSP). Incorporated in 2018, the company is based in Newburyport, Massachusetts.

Advano, also known as NanoStar, Inc., is a New Orleans-based company that specializes in silicon nanotechnology, focusing on the development of advanced silicon anode materials for lithium-ion batteries. Founded in 2014 and a graduate of Y Combinator in 2017, Advano offers scalable solutions that enhance the energy density and longevity of lithium-ion batteries by integrating or replacing traditional graphite components. Its innovative products cater to various industries, including electric vehicles and consumer electronics, and are designed to improve energy storage and charging capabilities. By providing low-cost, high-performance materials, Advano aims to support the domestic battery supply chain and facilitate the transition to sustainable energy solutions.

ChemomAb Ltd. is a clinical-stage biotechnology company based in Tel Aviv, Israel, specializing in the development of therapeutic antibodies for autoimmune and inflammatory diseases. The company focuses on addressing fibrosis-related conditions that present significant unmet medical needs. ChemomAb's lead product, CM-101, is a monoclonal antibody designed to inhibit the activity of the soluble protein CCL24, which plays a crucial role in promoting fibrosis and inflammation. CM-101 is currently undergoing clinical development, with a primary emphasis on orphan diseases such as Primary Sclerosing Cholangitis (PSC) and Systemic Sclerosis (SSc). The company is advancing three Phase 2 clinical trials for CM-101 in various fibrotic indications, with data anticipated to be reported in the near future.

EnClear Therapies develops device-based therapies for treating neurodegenerative diseases by removing toxic proteins from cerebrospinal fluid. Its initial targets are Amyotrophic Lateral Sclerosis (ALS) and Progressive Supranuclear Palsy (PSP). Incorporated in 2018, the company is based in Newburyport, Massachusetts.

SPARK Neuro Inc. is a neuroscience company focused on quantifying brain data to enhance audience engagement in the advertising and entertainment sectors, as well as improving clinical care and therapeutic discovery in healthcare. Founded in 2013 and headquartered in New York, the company utilizes advanced neuroscience tools, including patented neural metrics and machine learning algorithms, to analyze brain activity. Its flagship product, SPARK Scan, is a 10-minute EEG-based evaluation that detects early signs of changes in brain function. By partnering with prestigious institutions, SPARK Neuro aims to deepen the understanding of neurological and psychiatric conditions while making brain health measurement and care more accessible for healthcare professionals.

Founded in 2014, Compass Therapeutics is a clinical-stage biopharmaceutical company developing antibody therapeutics to treat solid tumors and hematological malignancies. Its pipeline includes CTX-471, an agonistic antibody of CD137 for immune cell activation, currently in Phase I trials; CTX-8371, a bispecific antibody targeting PD-1 and PD-L1, in IND-enabling studies; and CTX-009, a bispecific antibody inhibiting DLL4 and VEGF-A signaling, completed Phase I and is in Phase Ib combination with chemotherapy.

Terminal Inc., established in 2017 with headquarters in San Francisco and offices across North America and Mexico, specializes in talent solutions for technology companies. The company facilitates the recruitment, onboarding, and management of remote global engineering teams, enabling businesses to scale efficiently. Terminal offers global talent acquisition services, market insights, operational support including HR, benefits, payroll, and stock option administration, along with access to a connected tech community.

Invicta Medical develops innovative medical technologies for advanced sleep apnea treatments. Founded in 2013, the company is headquartered in Santa Clara, California.

ImmunoChina Pharmaceuticals manufactures medical products. The Company produces cell injections, cell therapy drugs, and other products. ImmunoChina Pharmaceuticals also provides medical technology development, medical research, medical trial development, and other services.

Founded in 2017, 3T Biosciences is a biotechnology company based in Menlo Park, California. It specializes in immunotherapies for cancer treatment.

Founded in 2014, Compass Therapeutics is a clinical-stage biopharmaceutical company developing antibody therapeutics to treat solid tumors and hematological malignancies. Its pipeline includes CTX-471, an agonistic antibody of CD137 for immune cell activation, currently in Phase I trials; CTX-8371, a bispecific antibody targeting PD-1 and PD-L1, in IND-enabling studies; and CTX-009, a bispecific antibody inhibiting DLL4 and VEGF-A signaling, completed Phase I and is in Phase Ib combination with chemotherapy.

Angiex is a biotechnology company developing vascular-targeted therapies for solid cancers. Founded by renowned scientists, Angiex focuses on fundamental aspects of endothelial biology, particularly angiogenesis. Its lead product is an antibody-drug conjugate therapy designed to deliver conjugated payloads directly to the nucleus in tumor cells and activated endothelium.

Invicta Medical develops innovative medical technologies for advanced sleep apnea treatments. Founded in 2013, the company is headquartered in Santa Clara, California.

Legendary Entertainment is a media company that specializes in creating and distributing content for television and digital platforms globally. The company engages in the development, co-production, co-financing, and distribution of motion pictures, collaborating with other production studios to enhance its offerings. Legendary Entertainment is dedicated to producing content that appeals to mainstream audiences, with a particular emphasis on the influential fandom demographic. Its portfolio includes box-office films, television shows, and comic storylines, reflecting a commitment to delivering engaging entertainment across various media formats.